Lack of association between glutathione S-transferase-MI, -TI, and -PI polymorphisms and olanzapine-induced weight gain in Korean schizophrenic patients

Psychiatry Investigation

Volumn 7, Issue 2, 2010, Pages 147-152

  Park, Young Min ^a   Lee, Heon Jeong ^b   Kang, Seung Gul ^b   Choi, Jung Eun ^b   Cho, Jae Hyuck ^a   Kim, Leen ^b  

^a Inje University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Glutathione S transferase; Olanzapine; Polymorphism; Weight gain

Indexed keywords

GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; OLANZAPINE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; KOREA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OXIDATIVE STRESS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 77954420384     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2010.7.2.147     Document Type: Article

References (44)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696. (Pubitemid 29517559)
2. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-432. (Pubitemid 30365564)
3. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003;54:565-567. (Pubitemid 36752990)
4. Strassnig M, Brar JS, Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res 2003;62:73-76. (Pubitemid 36588705)
5. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60 Suppl 21:25-30.
6. Vauth R, Löschmann C, Rüsch N, Corrigan PW. Understanding adherence to neuroleptic treatment in schizophreniaí. Psychiatry Res 2004; 126:43-49. (Pubitemid 38479794)
7. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-228.
8. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001;62 Suppl 7:4-10.
9. Pillai A, Parikh V, Terry AV Jr, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007;41:372-386. (Pubitemid 46201949)
10. Walss-Bass C, Weintraub ST, Hatch J, Mintz J, Chaudhuri AR. Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol 2008;11:1097-1104.
11. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006;136:3022-3026. (Pubitemid 44878567)
12. Eriksson JW. Metabolic stress in insulin's target cells leads to ROS accumulation-a hypothetical common pathway causing insulin resistance. FEBS Lett 2007;581:3734-3742.
13. Andreassen OA, Jørgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525-541.
14. Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab 2006;8:136-145.
15. Silva Mdo C, Gaspar J, Duarte Silva I, Faber A, Rueff J. GSTM1, GSTT1, and GSTP1 genotypes and the genotoxicity of hydroquinone in human lyphocytes. Environ Mol Mutagen 2004;43:258-264.
16. Mannervik B. The isoenzymes of glutathione transferase. Adv Enzymol Relat Areas Mol Biol 1985;57:357-417.
17. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 2000;61:154-166.
18. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440:944-948.
19. Kuzuya M, Ando F, Iguchi A, Shimokata H. Glutathione peroxidase 1 Pro198Leu variant contributes to the metabolic syndrome in men in a large Japanese cohort. Am J Clin Nutr 2008;87:1939-1944.
20. Lee YS, Kim AY, Choi JW, Kim M, Yasue S, Son HJ, et al. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol 2008;22:2176-2189.
21. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase θ (GSTT1): cDNA coloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-276.
22. Seidegård J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 1990;11:33-36.
23. Sundberg K, Johansson AS, Stenberg G, Widersten M, Seidel A, Mannervik B,et al. Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1-1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 1998;19:433-436.
24. Han OS, Hong JP. Structured Clinical Interview for DSM-IV Axis I Disorder-Korean Version. Seoul: Hana Medical Publishing; 2000.
25. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC, et al. Weight gain associated with the alpha2a-adrenergie receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006;141B:394-397.
26. Park YM, Cho JH, Kang SG, Choi JE, Lee SH, Kim L, et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008;33:55-60.
27. Kang SG, Lee HJ, Park YM, Choi JE, Han C, Kim YK, et al. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:160-163.
28. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Choi JE, et al. G-protein beta3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Investig 2009;6:39-43.
29. Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009;24:55-60.
30. Zhong SL, Zhou SF, Chen X, Chan SY, Chan E, Ng KY, et al. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 2006;28:77-85.
31. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003;19:376-382.
32. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001;69:138-147. (Pubitemid 32614026)
33. Motsinger AA, Ritchie MD. The effect of reduction in crossvalidation intervals on the performance of multifactor dimensionality reduction. Genet Epidemiol 2006;30:546-555.
34. Ritchie MD, Hahn LW, Moore JH. Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003;24:150-157.
35. Velez D, White BC, Motsinger AA, Bush WS, Ritchie MD, Williams SM, et al. A balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction. Genet Epidemiol 2007;31:306-315.
36. Brassat D, Motsinger AA, Caillier SJ, Erlich HA, Walker K, Steiner LL, et al. Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. Genes Immun 2006;7:310-315.
37. Motsinger AA, Brassat D, Caillier SJ, Erlich HA, Walker K, Steiner LL, et al. Complex gene-gene interactions in multiple sclerosis: a multifactorial approach reveals associations with inflammatory genes. Neurogenetics 2007;8:11-20.
38. Agirbasli D, Agirbasli M, Williams SM, Phillips JA 3rd. Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients. Coron Artery Dis 2006;17:413-417. (Pubitemid 44309780)
39. Hsieh CH, Liang KH, Hung YJ, Huang LC, Pei D, Liao YT, et al. Analysis of epistasis for diabetic nephropathy among type 2 diabetic patients. Hum Mol Genet 2006;15:2701-2708.
40. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17:189-212.
41. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001;17:888-895. (Pubitemid 33001657)
42. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998;71:1002-1012.
43. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28 Suppl 1:83-96.
44. Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK, et al. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment Prog Neuropsychopharmacol Biol Psychiatry 2007;31:673-677.